Trial · NCT03185481
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment-Emergent Adverse Events (All Causalities) | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Treatment-Emergent Adverse Events (Treatment Related) | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinically Significant Findings in Physical Examination | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period and had a post-baseline physical examination. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Clinically Significant Findings in Neurological Examination | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period and had a post-baseline neurological examination. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Abnormalities in Laboratory Test (Without Regard to Baseline Abnormality) | Baseline to last visit after termination(up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Vital Signs Data Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Vital Signs Data of Orthostatic Hypotension Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Electrocardiogram Data Meeting Pre-defined Criteria | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Worsening Suicidality and New Onset Suicidality | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Benzodiazepine Discontinuation Symptoms Based on Physician Withdrawal Checklist (PWC-20) | At last visit | The population for PWC-20 included participants who completed study treatment and who participated the first visit of follow-up | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline for Hauser Participant Diary Data in Daily OFF Time | Baseline, Day 21 and Day 35 | The study population included all participants who received at least 1 dose of study medication during the study period. | Hours | MEAN |
| SECONDARY | Change From Baseline for Hauser Participant Diary Data in Daily ON Time With Troublesome Dyskinesia | Baseline, Day 21 and Day 35 | The study population included all participants who received at least 1 dose of study medication during the study period. | Hours | MEAN |
| SECONDARY | Change From Baseline for Hauser Participant Diary Data in Daily ON Time Without Troublesome Dyskinesia | Baseline, Day 21 and Day 35 | The study population included all participants who received at least 1 dose of study medication during the study period. | Hours | MEAN |
| SECONDARY | Change From Baseline in Movement Disorder Society Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, III, IV, and Total Score | Baseline to last visit after termination (up to approximately 3 months) | The study population included all participants who received at least 1 dose of study medication during the study period. | Units on a scale | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03185481/outcomes